Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Executive Summary

Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.

Advertisement

Related Content

Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market
Dual Injection Approvals? A Comparison Of Indivior, Braeburn Buprenorphine Products
Recent And Upcoming FDA Advisory Committee Meetings
Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage
Trump's Opioid Commission Asks FDA To Boost Post-Market Vigilance
Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel